Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1124/jpet.124.002205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Methocinnamox is a Potent and Long-Acting Antagonist that can Prevent and Reverse Opioid-Induced Respiratory Depression.
J Pharmacol Exp Ther
September 2024
Department of Biology, Texas Tech University, Lubbock, Texas (J.A.C.) and Department of Biomedical Sciences, Marshall University, Huntington, West Virginia (D.J.M.)
Daily methocinnamox treatment dose-dependently attenuates fentanyl self-administration in rhesus monkeys.
Neuropharmacology
February 2024
Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX, 78229, USA; Addiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX, 78229, USA; Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX, 78229, USA. Electronic address:
Opioid use disorder and opioid overdose continue to be significant public health challenges despite the availability of effective treatments. Methocinnamox (MCAM) is a novel, long-acting opioid receptor antagonist that might be an effective treatment for opioid use disorder (i.e.
View Article and Find Full Text PDFBehavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder.
J Exp Anal Behav
March 2023
Department of Pharmacology, University of Texas Health Science Center at San Antonio, TX, United States.
Opioid overdose and opioid use disorder continue to be significant public health challenges despite the availability of effective medications and significant efforts at all levels of society. The emergence of highly potent and efficacious opioids such as fentanyl and its derivatives over the last decade has only exacerbated what was already a substantial problem. Behavioral pharmacology research has proven invaluable for understanding the effects of drugs as well as developing and evaluating pharmacotherapies for disorders involving the central nervous system, including substance abuse disorders.
View Article and Find Full Text PDFAttenuation of the Positive-Reinforcing Effects of Ultra-Potent Fentanyl Analogs, Along with Those of Fentanyl and Heroin, During Daily Treatment with Methocinnamox in Rhesus Monkeys.
J Pharmacol Exp Ther
March 2023
Department of Pharmacology (L.R.G., C.P.F.) and Department of Psychiatry (C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Addiction Research, Treatment, & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas (L.R.G., C.P.F.)
Without substantial intervention, the opioid crisis is projected to continue, underscoring the need to develop new treatments for opioid use disorder (OUD). One drug under development is the opioid receptor antagonist methocinnamox (MCAM), which appears to offer advantages over currently available medications; however, some questions remain about its potential utility, including its ability to block the effects of ultra-potent fentanyl analogs. The goal of this study was to examine its effectiveness in attenuating the abuse-related effects of the fentanyl analogs carfentanil and 3-methylfentanyl in monkeys responding for food or intravenous infusions under a choice procedure.
View Article and Find Full Text PDFMethocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.
J Pharmacol Exp Ther
April 2021
Departments of Pharmacology (V.M.J., G.C., C.P.F.), Psychiatry (C.P.F.), and Addiction Research, Treatment and Training Center of Excellence (V.M.J., G.C., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas
Opioid use disorder affects over 2 million Americans with an increasing number of deaths due to overdose from the synthetic opioid fentanyl and its analogs. The Food and Drug Administration-approved opioid receptor antagonist naloxone (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!